190 related articles for article (PubMed ID: 19627758)
1. [Medical treatment of primary hyperparathyroidism: role of calcimimetics].
Muñoz Torres M; García Martín A
Endocrinol Nutr; 2009 Apr; 56 Suppl 1():29-34. PubMed ID: 19627758
[TBL] [Abstract][Full Text] [Related]
2. MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly.
Filopanti M; Verga U; Ermetici F; Olgiati L; Eller-Vainicher C; Corbetta S; Persani L; Beck-Peccoz P; Spada A
Eur J Endocrinol; 2012 Aug; 167(2):157-64. PubMed ID: 22577108
[TBL] [Abstract][Full Text] [Related]
3. Cinacalcet for the treatment of primary hyperparathyroidism.
Dillon ML; Frazee LA
Am J Ther; 2011 Jul; 18(4):313-22. PubMed ID: 20228675
[TBL] [Abstract][Full Text] [Related]
4. Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1.
Del Prete M; Marotta V; Ramundo V; Marciello F; Di Sarno A; Esposito R; Carratù AC; De Luca Di Roseto C; Di Somma C; Colao A; Faggiano A
Minerva Endocrinol; 2013 Dec; 38(4):389-94. PubMed ID: 24285106
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism.
Nagano N
Pharmacol Ther; 2006 Mar; 109(3):339-65. PubMed ID: 16102839
[TBL] [Abstract][Full Text] [Related]
6. Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects.
Duntas LH; Stathatos N
Endocrine; 2011 Jun; 39(3):199-204. PubMed ID: 21442382
[TBL] [Abstract][Full Text] [Related]
7. Calcimimetics versus parathyroidectomy for treatment of primary hyperparathyroidism: retrospective chart analysis of a prospective database.
Keutgen XM; Buitrago D; Filicori F; Kundel A; Elemento O; Fahey TJ; Zarnegar R
Ann Surg; 2012 May; 255(5):981-5. PubMed ID: 22470074
[TBL] [Abstract][Full Text] [Related]
8. [Nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: focus on calciomimetics].
Brardi S; Ponchietti R; Duranti E
G Ital Nefrol; 2016; 33(6):. PubMed ID: 28134399
[TBL] [Abstract][Full Text] [Related]
9. Benefits and place of calcimimetics in the management of primary hyperparathyroidism.
Meier C
Ann Endocrinol (Paris); 2015 May; 76(2):163-4. PubMed ID: 25913524
[No Abstract] [Full Text] [Related]
10. [Cinacalcet--a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism].
Vestergaard P; Nielsen LR; Mosekilde L
Ugeskr Laeger; 2006 Jan; 168(1):29-32. PubMed ID: 16393559
[TBL] [Abstract][Full Text] [Related]
11. The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review.
Rodríguez M; Goodman WG; Liakopoulos V; Messa P; Wiecek A; Cunningham J
Semin Dial; 2015; 28(5):497-507. PubMed ID: 25752650
[TBL] [Abstract][Full Text] [Related]
12. [Calcimimetics].
Messa P; Como G; Brezzi B
G Ital Nefrol; 2006; 23(1):12-21. PubMed ID: 16521071
[TBL] [Abstract][Full Text] [Related]
13. The role of calcimimetics in the treatment of hyperparathyroidism.
Wüthrich RP; Martin D; Bilezikian JP
Eur J Clin Invest; 2007 Dec; 37(12):915-22. PubMed ID: 18036025
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl].
Nakanishi S; Fukagawa M
Clin Calcium; 2007 Jan; 17(1):88-92. PubMed ID: 17211098
[TBL] [Abstract][Full Text] [Related]
15. Medical management of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop.
Khan A; Grey A; Shoback D
J Clin Endocrinol Metab; 2009 Feb; 94(2):373-81. PubMed ID: 19193912
[TBL] [Abstract][Full Text] [Related]
16. Update on the use of cinacalcet in the management of primary hyperparathyroidism.
Marcocci C; Cetani F
J Endocrinol Invest; 2012 Jan; 35(1):90-5. PubMed ID: 22104762
[TBL] [Abstract][Full Text] [Related]
17. New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.
de Francisco AL
Expert Opin Pharmacother; 2008 Apr; 9(5):795-811. PubMed ID: 18345956
[TBL] [Abstract][Full Text] [Related]
18. Clinical utilization of cinacalcet in hypercalcemic conditions.
Messa P; Alfieri C; Brezzi B
Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):517-28. PubMed ID: 21361849
[TBL] [Abstract][Full Text] [Related]
19. Molecular and Clinical Aspects of the Target Therapy with the Calcimimetic Cinacalcet in the Treatment of Parathyroid Tumors.
Mingione A; Verdelli C; Terranegra A; Soldati L; Corbetta S
Curr Cancer Drug Targets; 2015; 15(7):563-74. PubMed ID: 26033088
[TBL] [Abstract][Full Text] [Related]
20. Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet.
Reh CM; Hendy GN; Cole DE; Jeandron DD
J Clin Endocrinol Metab; 2011 Apr; 96(4):E707-12. PubMed ID: 21289269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
